BRIEF-Spark Therapeutics and Pfizer announce data from first cohort in Hemophilia B Phase 1/2 trial

* Spark Therapeutics and Pfizer announce updated data from first cohort in Hemophilia B phase 1/2 trial demonstrating consistent, sustained therapeutic levels of factor ix activity
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.